References
- Wilkins E, Wilson L, Wickramasinghe K, et al. European cardiovascular disease statistics 2017. Brussels: European Heart Network; 2017
- Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129:S1-S45
- Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017;38:2459-72
- Gitt AK, Lautsch D, Ferrieres J, et al. Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients. Atherosclerosis 2016;255:200-9
- Task Force Members, Piepoli MF, Hoes AW, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 2016;252:207-74
- Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2016;37:2999-3058
- European Association for Cardiovascular Prevention, Rehabilitation, Reiner Z, et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818
- REPATHA® (evolocumab) prescribing information. Thousand Oaks, CA: Amgen Inc; 2016
- PRALUENT® (alirocumab) prescribing information. Bridgewater, NJ: Sanofi-Aventis; 2017
- Rane PB, Patel J, Harrison DJ, et al. Patient characteristics and real-world treatment patterns among early users of PCSK9 inhibitors. Am J Cardiovasc Drugs 2018;18(2)103-108
- Anderson P, Benford M, Harris N, et al. Real-world physician and patient behaviour across countries: disease-specific programmes - a means to understand. Curr Med Res Opin 2008;24:3063-72
- Babineaux SM, Curtis B, Holbrook T, et al. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the disease specific programme. BMJ Open 2016;6:e010352
- Sanidad MD. Informe de posicionamiento terapéutico de evolocumab (Repatha®) en hipercolesterolemia. 2016. Available at: https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT-evolocumab-repatha.pdf [Last accessed Sept 5, 2018]
- National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst Monog 2001;2001(30):5-15
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
- Hovingh GK, Gandra SR, McKendrick J, et al. Identification and management of patients with statin-associated symptoms in clinical practice: a clinician survey. Atherosclerosis 2016;245:111-17
- Zafrir B, Jubran A. Lipid-lowering therapy with PCSK9-inhibitors in the real-world setting: two-year experience of a regional lipid clinic. Cardiovasc Ther 2018;36(5):e12439
- Stoekenbroek RM, Hartgers ML, Rutte R, et al. PCSK9 inhibitors in clinical practice: delivering on the promise? Atherosclerosis 2018;270:205-10
- Razek O, Cermakova L, Armani H, et al. Attainment of recommended lipid targets in patients with familial hypercholesterolemia: real-world experience with PCSK9 inhibitors. Can J Cardiol 2018;34:1004-9
- Virani SS, Kennedy KF, Akeroyd JM, et al. Variation in lipid-lowering therapy use in patients with low-density lipoprotein cholesterol >/=190 mg/dL: insights from the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry. Circ Cardiovasc Qual Outcomes 2018;11:e004652
- World Health Organization. Body mass index classification. World Health Organization, 2018. Available at: http://apps.who.int/bmi/index.jsp?introPage=intro_3.html [Last accessed April 11, 2018]
- Ray K, Bruckert E, Annemans L, et al. Characteristics of patients prescribed Evolocumab in Europe. Does clinical use match clinical guidelines? European Heart Journal 2018;39(supp 1):ehy565.P1699